Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Gastrointestinal Drug Market to 2022 - TNF Inhibitors & PPIs Continue to Dominate Therapy Landscape - Research and Markets

Research and Markets
Posted on: 01 Nov 16

Research and Markets has announced the addition of the "Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape" report to their offering.

The global revenue for the gastrointestinal market is forecast to grow at a CAGR of 4.45%, from $35.7 billion in 2015 to $48.4 billion in 2022.

The gastrointestinal market landscape is expected to change substantially with the advent of promising novel pipeline products. There are 937 gastrointestinal pipeline products in active development, of which small molecules and biologics account for 53% and 38%, respectively.

Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).

Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.

Companies Mentioned:

  • AbbVie
  • Alexion
  • Allergan
  • AstraZeneca
  • Celgene
  • Johnson & Johnson
  • Novo Nordisk
  • Synergy Pharmaceuticals
  • Takeda

Key Topics Covered:

1 List of Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2022

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/2pn63g/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006317/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.